Literature DB >> 26328257

Prognostic value of the IASLC/ATS/ERS classification and IMP3 expression in lung adenocarcinoma of Chinese cases.

Xiangjie Sun1, Ping Wei2, Chen Shen1, Yusi Yang1, Yiqin Wang1, Yuan Li1, Xiang Du1.   

Abstract

The IASLC/ATS/ERS classification system was proposed in 2011 to improve the histological subtypes of lung adenocarcinoma, while the prognostic value of the combination of histological predominant subtypes is not consistent. IMP3 is an oncofetal protein which has been proved associated with aggressive tumor behavior in malignancies, but few reports were investigated in lung adenocarcinoma. The aim of this study is to explore the prognostic value of the IASLC/ATS/ERS classification and IMP3 expression in lung adenocarcinoma of Chinese cases. A total of 196 cases were classified according to the IASLC/ATS/ERS classification system and immunohistochemically analyzed by using a monoclonal antibody against IMP3. Univariate survival analysis indicated patients with solid-predominant subtype had shorter disease-free survival (P = 0.003) and overall survival (P = 0.014) compared to those with non-solid predominant subtype. Multivariate survival analysis revealed that solid-predominant subtype could be an independent prognostic factor for disease-free survival (HR: 1.22, 95% CI: 1.05-1.41; P = 0.008). Analysis of IMP3 expression showed that IMP3 was more frequently overexpressed in tumors with advanced pTNM stage (P < 0.001), larger tumor size (P = 0.036), poorer histological differentiation (P < 0.001), lymph node metastasis (P < 0.001), and solid-predominant subtype (P < 0.001). Survival analysis also confirmed that patients in IMP3 high-expression group had both worse disease-free survival (P = 0.039) and overall survival (P = 0.029) than those in IMP3 low-expression group. Our results illustrated that solid-predominant subtype according to the IASLC/ATS/ERS classification is an independent prognostic factor, and IMP3 overexpression is associated with aggressive tumor behavior and poor clinical outcome in lung adenocarcinoma.

Entities:  

Keywords:  IMP3; Lung adenocarcinoma; subtype; survival

Year:  2015        PMID: 26328257      PMCID: PMC4548338     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  45 in total

1.  A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development.

Authors:  J Nielsen; J Christiansen; J Lykke-Andersen; A H Johnsen; U M Wewer; F C Nielsen
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

2.  High insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer.

Authors:  Tibor Szarvas; Frank vom Dorp; Christian Niedworok; Ariane Melchior-Becker; Jens W Fischer; Bernhard B Singer; Henning Reis; Ágnes Bánkfalvi; Kurt W Schmid; Imre Romics; Süleyman Ergün; Herbert Rübben
Journal:  BJU Int       Date:  2012-04-13       Impact factor: 5.588

3.  High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not.

Authors:  Haodong Xu; Patricia A Bourne; Betsy O Spaulding; Hanlin L Wang
Journal:  Hum Pathol       Date:  2007-02-20       Impact factor: 3.466

4.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

5.  IMP3 expression is correlated with histologic grade of lung adenocarcinoma.

Authors:  Jennifer J Findeis-Hosey; Qi Yang; Betsy O Spaulding; Hanlin L Wang; Haodong Xu
Journal:  Hum Pathol       Date:  2009-12-11       Impact factor: 3.466

6.  Time trends in cancer mortality in China: 1987-1999.

Authors:  Ling Yang; Donald M Parkin; Liandi Li; Yude Chen
Journal:  Int J Cancer       Date:  2003-09-20       Impact factor: 7.396

7.  IMP3 expression is associated with poor survival in cervical squamous cell carcinoma.

Authors:  Qingzhu Wei; Jinhai Yan; Bo Fu; Jianghuan Liu; Ling Zhong; Qiao Yang; Tong Zhao
Journal:  Hum Pathol       Date:  2014-07-30       Impact factor: 3.466

Review 8.  Subtyping lung adenocarcinoma according to the novel 2011 IASLC/ATS/ERS classification: correlation with patient prognosis.

Authors:  Morihito Okada
Journal:  Thorac Surg Clin       Date:  2013-02-07       Impact factor: 1.750

9.  Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance.

Authors:  Oluwole Fadare; Sharon X Liang; Marta A Crispens; Howard W Jones; Dineo Khabele; Katja Gwin; Wenxin Zheng; Khaled Mohammed; Vinita Parkash; Jonathan L Hecht; Mohamed M Desouki
Journal:  Hum Pathol       Date:  2013-03-01       Impact factor: 3.466

10.  Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.

Authors:  Noriko Motoi; Janos Szoke; Gregory J Riely; Venkatraman E Seshan; Mark G Kris; Valerie W Rusch; William L Gerald; William D Travis
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

View more
  4 in total

1.  IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression.

Authors:  Qin Zhu; Yuqing Qu; Qiongyan Zhang; Linghui Lu; Weiwei Weng; Hao Zhang; Lihong Zhang; Yan Ning; Yiqin Wang
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

2.  Prognostic value of high IMP3 expression in solid tumors: a meta-analysis.

Authors:  Luyao Chen; Yongpeng Xie; Xintao Li; Liangyou Gu; Yu Gao; Lu Tang; Jianwen Chen; Xu Zhang
Journal:  Onco Targets Ther       Date:  2017-06-06       Impact factor: 4.147

3.  Characterization of novel small non-coding RNAs and their modifications in bladder cancer using an updated small RNA-seq workflow.

Authors:  Zhangli Su; Ida Monshaugen; Arne Klungland; Rune Ougland; Anindya Dutta
Journal:  Front Mol Biosci       Date:  2022-07-18

4.  Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma.

Authors:  Yongfeng Yu; Zhengping Ding; Hong Jian; Lan Shen; Lei Zhu; Shun Lu
Journal:  Cancer Med       Date:  2016-07-25       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.